Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine

NCT ID: NCT02263248

Last Updated: 2018-07-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 56 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-12-31
• Study Completion Date: 2018-05-01

Brief Summary

The Investigators are conducting a research study to learn about the safety and benefit of using a medication called buprenorphine for patient with difficult to treat depression . This research study is testing whether combining two medications will be effective in treating depression when initial treatment with just one antidepressant does not relieve the depressive symptoms ; this is what is called " difficult to treat depression " or " treatment resistant depression ". The two medication the investigators are using are " an anti-depressant medication called venlafaxine XR ( the generic form of Effexor ) and buprenorphine . Buprenorphine is a medication that is FDA approved for the treatment of opioid dependence. The investigators are testing whether adding buprenorphine to venlafaxine enhances treatment response.

Detailed Description

The aim of this study is to examine the feasibility, safety, and tolerability of buprenorphine (BPN) as a novel treatment for late-life treatment resistant depression (LL-TRD). The investigators aim to use a clinical trial methodology common to all three sites, and to examine the mechanism of action (MOA) of BPN using translational neuroscience methods. Over ½ of seniors with depression fail to respond to traditional antidepressants.19,20 Modulation of the opiate system with BPN offers a novel mechanistic approach to improve the lives of patients with LL-TRD, with a safety profile potentially superior to current augmentation strategies such as antipsychotics, lithium, ECT, and surgical interventions (e.g., deep brain or vagal nerve stimulation).

Conditions

Major Depressive Disorder; Depression

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

venlafaxine XR plus buprenorphine

Drug Intervention: venlafaxine XR plus buprenorphine Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks.

Group Type: EXPERIMENTAL

venlafaxine

Intervention Type: DRUG

slow titration to a maximum of 300 mg per day. will remain on venlafaxine XR for upto 32 weeks.

buprenorphine

Intervention Type: DRUG

randomized to either buprenorphine or placebo, dose range from 0.2 mg qd/ to 1.2 mg qd

venlafaxine XR plus placebo

Drug Intervention: venlafaxine XR plus placebo Dosage varies . Subject remains on antidepressant throughout the 32 weeks study. Will be randomized to buprenorphine or placebo for up to 16 weeks

Group Type: PLACEBO_COMPARATOR

venlafaxine

Intervention Type: DRUG

slow titration to a maximum of 300 mg per day. will remain on venlafaxine XR for upto 32 weeks.

placebo

Intervention Type: DRUG

patients will remain on venlafaxine XR and be randomzied to receive either placebo or buprenorphine for 8 weeks. at the end of 8 weeks those who did not receive buprenorphine will be given an opportunity to try it.

Interventions

venlafaxine

slow titration to a maximum of 300 mg per day. will remain on venlafaxine XR for upto 32 weeks.

Intervention Type: DRUG

buprenorphine

randomized to either buprenorphine or placebo, dose range from 0.2 mg qd/ to 1.2 mg qd

Intervention Type: DRUG

placebo

patients will remain on venlafaxine XR and be randomzied to receive either placebo or buprenorphine for 8 weeks. at the end of 8 weeks those who did not receive buprenorphine will be given an opportunity to try it.

Intervention Type: DRUG

Other Intervention Names

Effexor; Temgesic; Subutex; Suboxone

Eligibility Criteria

Inclusion Criteria

1. Age > 50 years

2. Major depressive disorder (MDD), single or recurrent, as diagnosed by the SCID-IV (or SCID-5 if available)

3. MADRS > 15

4. Has or agrees to establish a clinical relationship with primary care physician (PCP).

5. Availability of an informant (e.g., emergency contact) is encouraged but not required for study participation

Exclusion Criteria

1. Inability to provide informed consent

2. Depressive symptoms not severe enough (i.e., MADRS < 15) at the baseline assessments

3. Dementia, as defined by 3MS < 80 and clinical evidence of dementia

4. Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms, as diagnosed by the SCID

5. Abuse of or dependence on alcohol or other substances within the past 3 months as determined by SCID, and score of > 8 on AUDIT-C and confirmed by study physician interview

6. High risk for suicide (e.g., active SI and/or current/recent intent or plan) AND unable to be managed safely in the clinical trial (e.g., unwilling to be hospitalized). Urgent psychiatric referral will be made in these cases

7. Contraindication to venlafaxine or buprenorphine as determined by PCP and study physician including history of intolerance of either venlafaxine or buprenorphine in the study target dosage range (venlafaxine at up to 300 mg/day; buprenorphine at up to 1.2 mg/day)

8. Inability to communicate in English (i.e., interview cannot be conducted without an interpreter; subject largely unable to understand questions and cannot respond in English)

9. Non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview)

10. Unstable medical illness, including delirium, uncontrolled diabetes mellitus, hypertension, hyperlipidemia, or cerebrovascular or cardiovascular risk factors that are not under medical management. This will be determined based on information from the patient's personal physician and study physician's clinical judgment. Referral to the patient's personal physician or to a general practitioner will be made in these cases

11. Subjects taking psychotropic medications that cannot be safely tapered and discontinued prior to study initiation. The following exceptions are allowed if they have been taken at a stable dose for at least 4 weeks prior to study entry and there is not a plan to change the dose during the next 32 -36 weeks: benzodiazepines up to 2 mg/d lorazepam equivalent; other sedative-hypnotics (e.g., zolpidem, zaleplon, eszopiclone); gabapentin if prescribed for non-psychiatric indication (e.g., neuropathy)

12. History of opiate abuse or dependence

13. Severe pain, defined as > 7 on 0-10 numeric rating scale for pain

14. Concomitant use of strong or moderate CYP3A4 inhibitor (indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketonazole, nefazodone, saquinovir, telithromycin, aprepitant, erythromycin, fluconazole, grapefruit juice, verapamil, diltiazem)

15. Refusal to stop all opioids (to avoid precipitating opioid withdrawal)

16. Refusal to discontinue all alcohol (to reduce the risk of respiratory depression)

17. Hepatic impairment (AST/ALT > 1.5 times upper normal)

18. Estimated Glomerular Filtration Rate (GFR) < 20 ml/min

19. Inability/refusal to identify a person as an emergency contact

-

• Minimum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Reckitt Benckiser LLC

INDUSTRY

Sponsor Role: collaborator

Centre for Addiction and Mental Health

OTHER

Sponsor Role: lead

Responsible Party

Daniel Blumberger

Dr. Daniel. M. Blumberger

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Daniel M Blumberger, MD

Role: PRINCIPAL_INVESTIGATOR

CAMH

Locations

Centre for Addiction and Mental Health

Toronto, Ontario, Canada

Countries

Canada

References

Buchalter ELF, Oughli HA, Lenze EJ, Dixon D, Miller JP, Blumberger DM, Karp JF, Reynolds CF 3rd, Mulsant BH. Predicting Remission in Late-Life Major Depression: A Clinical Algorithm Based Upon Past Treatment History. J Clin Psychiatry. 2019 Dec 10;80(6):18m12483. doi: 10.4088/JCP.18m12483.

Reference Type: DERIVED

PMID: 31846575 (View on PubMed)

Other Identifiers

035/2014

Identifier Type: -

Identifier Source: org_study_id